Opinion|Videos|November 18, 2026

Comparing CELMoD Treatment Strategies in Relapsed/Refractory Multiple Myeloma

The faculty discuss how to contextualize the findings from SUCCESSOR-2 and EXCALIBER-RRMM when considering treatment options for patients with relapsed/refractory multiple myeloma.

Episodes in this series

The faculty discuss how to contextualize the findings from SUCCESSOR-2 and EXCALIBER-RRMM when considering treatment options for patients with relapsed/refractory multiple myeloma. They highlight the differences in trial populations, noting that SUCCESSOR-2 included a more heavily pretreated population with substantial anti-CD38-refractory disease, whereas EXCALIBER-RRMM primarily evaluated patients with one or two prior lines of therapy and limited prior anti-CD38 exposure. The panel considers how mezigdomide- and iberdomide-based regimens may address different clinical needs, depending on prior treatment, disease characteristics, and the intensity of therapy required. Faculty also compare these approaches with T-cell-redirecting therapies, discussing treatment logistics, toxicity, and the potential impact on quality of life. Safety considerations include neutropenia, infection risk, and thromboembolic events, with panelists noting that familiarity with immunomodulatory drugs may help clinicians manage some of these risks. The discussion emphasizes the need to evaluate efficacy and safety in the context of each patient's circumstances and to consider how CELMoD-based regimens may fit into treatment sequencing in both academic and community practice.


Related to this article